Bayer (BAYN) Stock Overview

Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. More details

BAYN fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 57.1% below our estimate of its fair value

Earnings are forecast to grow 41.22% per year

Risk Analysis

Shares are highly illiquid

BAYN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW446,702 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

446,702 investors already sharing narratives

View all narratives

Bayer Aktiengesellschaft Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bayer
Historical stock prices
Current Share Price	€30,000.00
52 Week High	€33,000.00
52 Week Low	€26,000.00
Beta	0.83
1 Month Change	-2.66%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	116,406.02%

Recent updates

Shareholder Returns

	BAYN	AR Pharmaceuticals	AR Market
7D	-4.6%	-0.8%	2.3%
1Y	n/a	19.2%	70.2%

Return vs Industry: Insufficient data to determine how BAYN performed against the AR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BAYN performed against the AR Market.

Price Volatility

Is BAYN's price volatile compared to industry and market?
BAYN volatility
BAYN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.4%
Market Average Movement	4.4%
10% most volatile stocks in AR Market	6.4%
10% least volatile stocks in AR Market	3.0%

Stable Share Price: BAYN's share price has been volatile over the past 3 months compared to the AR market.

Volatility Over Time: Insufficient data to determine BAYN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1863	87,830	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.

Bayer Aktiengesellschaft Fundamentals Summary

How do Bayer's earnings and revenue compare to its market cap?
BAYN fundamental statistics
Market cap	AR$83.12t
Earnings (TTM)	-AR$3.02t
Revenue (TTM)	AR$78.92t

1.1x

P/S Ratio

-27.5x

P/E Ratio

Is BAYN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BAYN income statement (TTM)
Revenue	€45.38b
Cost of Revenue	€17.94b
Gross Profit	€27.43b
Other Expenses	€29.17b
Earnings	-€1.74b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 03, 2026

Earnings per share (EPS)	-1.77
Gross Margin	60.46%
Net Profit Margin	-3.83%
Debt/Equity Ratio	124.8%

How did BAYN perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

-6%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/15 18:17
End of Day Share Price	2026/09/15 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bayer Aktiengesellschaft is covered by 41 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Rafael Bonardell Trianes	Banco de Sabadell. S.A.
Charles Pitman	Barclays
"Charles Pitman-King	Barclays

Bayer (BAYN) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Bayer Aktiengesellschaft Competitors

Takeda Pharmaceutical

Merck KGaA

Galderma Group

Haleon

Price History & Performance

Recent News & Updates

Bayer Group Receives U.S. FDA Accelerated Approval For Sevabertinib As First-Line Treatment Option For Adults With HER2-Mutant Non-Small Cell Lung Cancer

Bayer Initiates Phase II Study of Investigational Girk4 Inhibitor in Patients with Atrial Fibrillation

Bayer Presents Phase III Reveal Study Results For Investigational Pet Radiotracer Iodine 124 Evuzamitide

Bayer Group Receives Approval For Sevabertinib In Japan For HER2-Mutant Non-Small Cell Lung Cancer

One A Day Introduces New Women's Multi Gummy Formula With 1,000 Mcg Biotin

Bayer Group to Consolidate U.S. Glyphosate Business into Distinct Entity Operating as Ruveon

Recent updates

Bayer Group Receives U.S. FDA Accelerated Approval For Sevabertinib As First-Line Treatment Option For Adults With HER2-Mutant Non-Small Cell Lung Cancer

Bayer Initiates Phase II Study of Investigational Girk4 Inhibitor in Patients with Atrial Fibrillation

Bayer Presents Phase III Reveal Study Results For Investigational Pet Radiotracer Iodine 124 Evuzamitide

Bayer Group Receives Approval For Sevabertinib In Japan For HER2-Mutant Non-Small Cell Lung Cancer

One A Day Introduces New Women's Multi Gummy Formula With 1,000 Mcg Biotin

Bayer Group to Consolidate U.S. Glyphosate Business into Distinct Entity Operating as Ruveon

Bayer Appoints Kacy Perry as Country Division Head for Crop Science Canada, Effective July 1, 2026

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Perfuse Therapeutics, Inc from Hatteras Venture Partners V, LP managed by Hatteras Venture Advisors VI, LLC, OrbiMed Advisors LLC and Access Industries (uk) Ltd.

Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity

Bayer Appoints Jost Reinhard as President of Radiology Business Within Bayer's Pharmaceuticals Division, Effective August 1, 2026

Bayer AG Announces Executive Changes

Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease

Bayer Presents First Full FIND-CKD Results Investigating KERENDIA in Non-Diabetic Chronic Kidney Disease and Infinity Pooled Analysis At ERA 2026

Bayer Presents New Data Across Oncology Portfolio

Bayer Announces Priority Review Of Supplemental New Drug Application For Kerendia For Treatment Of Adults With Type 1 Diabetes And Chronic Kidney Disease

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

Bayer Receives U.S. FDA Priority Review For Hyrnuo As First-Line Treatment Of Her2-Mutated Non-Small Cell Lung Cancer

Bayer Announces Positive Topline Results from the Phase III REVEAL Study

Bayer Aktiengesellschaft (XTRA:BAYN) entered into an agreement to acquire Perfuse Therapeutics, Inc. for $2.5 billion.

Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026

Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney Disease

Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027

Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026

Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future Claims

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims

Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke Prevention

Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease

Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome

Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial Hyperplasia

Bayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexian

U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Bayer Aktiengesellschaft to Report Q2, 2026 Results on Aug 04, 2026

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces New Phase III Investigational Data from the Pivotal Fine-One Trial

Bayer Announces U.S. Food and Drug Administration Approval for Moderate to Severe Hot Flashes Due to Menopause

Hesperos and Bayer Consumer Health Develop First Human-On-A-Chip Model of Stress-Induced Cognitive Dysfunction

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's Disease

Bayer®? Aspirin Introduces Aspirina to the U.S. Pain Market

Bayer Aktiengesellschaft to Report Q1, 2026 Results on May 12, 2026

Bayer Aktiengesellschaft to Report Q3, 2025 Results on Nov 12, 2025

Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases

Bayer Announces Executive Changes for North America

Bayer Files for Approval of Gadoquatrane to the US Food and Drug Administration

U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer

Vividion Therapeutics, Inc. and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study as Per Bayer

Bayer's XOFIGO (Radium-223 Dectloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Bayer Highlights New Data from Oncology and Women’S Health Portfolios At 2025 Asco Annual Meeting

Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular Carcinoma

Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025

Bayer to Unveil Latest NUBEQA®? (Darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting

Bayer Receives Full FDA Approval For VITRAKVI®? As First-In-Class TRK Inhibitor

Elliott Reportedly Gauge Investor Interest in Bayer's Consumer Health Business

Bayer Announces Management Changes, Effective April 15, 2025

Bayer Announces U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA®? (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%

Bayer Introduces Vyconic Soybeans at Commodity Classic 2025

Shareholder Returns

Price Volatility